Clinical trials: Non Alcoholic Fatty Liver
Nonalcoholic Fatty Liver Disease
An Intervention Study of Compound Silymarin in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China. The aim of this project is to evaluate the effects of compound silymarin on biomarkers of lipid metabolism and inflammation in the…
- Trial name
- NCT05497765
- Testing
- Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza, Silibinin extract
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Guangzhou Medical University
Fatty Liver, Nutritional and Metabolic Disease
Low GI Diet Effects on Non-Alcoholic Fatty Liver Disease
A 2 x 2 cross-over dietary intervention trial designed to investigate the effects of low glycemic index (LGI) versus high glycemic index (HGI) diet on hepatic fat accumulation and gut microbiota composition in participants with…
- Trial name
- LGI-NAFLD (NCT04415632)
- Testing
- low glycemic index diet, High glycemic index diet
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Nottingham
Non-alcoholic Fatty Liver Disease (NAFLD)
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
The goal of this observational, cross-sectional, case-control clinical study is to investigate the metabolic adaptations underlying the progression of nonalcoholic fatty liver disease (NAFLD), and to test the hypothesis that…
- Trial name
- ECHO (NCT06942312)
- Testing
- Ketoisocaproic acid breath test, Ammonium Chloride, Bicarbonate de sodium
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Depressive Disorder, Depression
The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity
The trial will be a four-arm, parallel group, prospective, randomized, double-blind, controlled design that will include 200 participants and will last 20 weeks.
- Conditions
- Depressive Disorder, Depression, Anxiety, Stress
- Trial name
- PRO-DEMET (NCT04756544)
- Testing
- Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Medical University of Lodz
Non Alcoholic Steatohepatitis
Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis.
The aims of this study are as follows: To compare the role of alternate-day fasting over standard medical management alone to reverse NASH.
- Trial name
- NCT06676813
- Testing
- Alternate day fasting
- Where
- India
- Volunteers
- 72 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatic Impairment, Healthy Participants
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
The study is proposed to characterize the effect of varying degrees of hepatic impairment on the plasma PK of PF-06835919
- Trial name
- NCT04193436
- Testing
- PF-06835919 25 mg
- Where
- 3 sites in Belgium, Czechia and 1 more
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
NASH - Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate
Gut Permeability and Bariatric-metabolic Surgery
Increased intestinal permeability and dysbiosis have been causally associated with NAFLD and NASH progression. However, to date, there are no systematic studies, on the effect of bariatric-metabolic surgery on intestinal…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Intestinal Permeability
- Trial name
- NCT05257200
- Where
- Austria
- Volunteers
- 125 people
- Sponsor
- Medical University of Vienna
Fatty Liver, Dyslipidemias
Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
The purpose of the study is to compare the impact of atorvastatin 20mg qd and Vitamin E 300mg qd therapy on liver fat content in patients with type 2 diabetes associated with high LDL-C and non-alcoholic fatty liver disease.
- Conditions
- Fatty Liver, Dyslipidemias, Diabetes Mellitus
- Trial name
- NCT01720719
- Testing
- atorvastatin, Vitamin E
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xin Gao
Non-alcoholic Steatohepatitis
Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis
Non-alcoholic fatty liver disease (NAFLD), estimated to be 17% prevalent in France, can lead to non-alcoholic steatohepatitis (NASH), which in turn can progress to fibrosis, the ultimate stage of which is cirrhosis, a major cause…
- Trial name
- HEFITEP (NCT06160271)
- Testing
- PET scan of 68Ga-FAPI
- Volunteers
- 72 people
- Sponsor
- Central Hospital, Nancy, France
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults
Nonalcoholic fatty liver disease (NAFLD) is a global health concern with a suspected increasing prevalence due to the rise in obesity and diabetes mellitus.
- Trial name
- PREV (NCT03142867)
- Testing
- non-applicable
- Where
- United States
- Volunteers
- 826 people, healthy volunteers welcome
- Sponsor
- The Geneva Foundation
Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight
Hepatoprotective Measures for Children at High Risk of NAFLD
Non Alcoholic Fatty Liver Disease (NAFLD) is a spectrum of disease, ranging from simple fatty deposition (steatosis) to inflammation (steatohepatitis), fibrosis, cirrhosis, and end-stage liver failure.
- Conditions
- Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight, Acute Lymphoblastic Leukemia
- Trial name
- NCT06918080
- Testing
- Ursodeoxycholic Acid 250 Mg Oral Capsule, Omega -3 fatty acids, Physical exercise
- Where
- 2 sites in Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
NASH - Nonalcoholic Steatohepatitis
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
To evaluate the safety, tolerability and Pharmacokinetic profile of SNP-630 when oral administered to healthy subjects.
- Trial name
- NCT04808154
- Testing
- SNP-630
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sinew Pharma Inc.
Non-Alcoholic Steatohepatitis
A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831
The aim of this study is to explore the effect of a new drug (ASP9831) in patients with non-alcoholic steatohepatitis (NASH) by assessing clinical signs, laboratory data and biomarkers during a 12 week treatment period
- Trial name
- ASTER (NCT00668070)
- Testing
- ASP9831
- Where
- 30 sites in Belgium, Czechia and 5 more
- Volunteers
- 114 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes, Nonalcoholic Fatty Liver Disease
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
This study is designed to study the effect of vitamin D intake on the severity of fatty liver and poor glucose control in patients with type 2 diabetes and fatty liver disease.
- Conditions
- Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency
- Trial name
- VDLS (NCT02132442)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Massachusetts, Worcester
Obesity, NAFLD
Bariatric Endoscopy and NAFLD
Find out how bariatric endocopy will influence clinical course of non alcoholic fatty liver disease.
- Conditions
- Obesity, NAFLD, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT04669470
- Testing
- bariatric endoscopy, mainly intragastric baloons, plication of stomach too
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University of Ostrava
Acute Pancreatitis, Nonalcoholic Fatty Liver Disease
Association Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis
The early evaluation of AP severity are vital. Previous studies have shown non-alcoholic fatty liver disease (NAFLD) is associated with severity of acute pancreatitis (AP).
- Trial name
- NCT03566173
- Where
- China
- Volunteers
- 1,662 people
- Sponsor
- Ningbo No. 1 Hospital
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes
Antidiabetic Drugs for Steatotic Liver Disease
To investigate the synergic therapeutic effect of thiazolidinediones and SGLT2 inhibitor on metabolic dysfunction-associated steatotic liver disease, the effect of empagliflozin 10mg, pioglitazone 15mg monotherapy and combination…
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases
- Trial name
- NCT03646292
- Testing
- Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Yonsei University
NAFLD
Serum Selenium and Zinc Levels in Non-alcoholic Fatty Liver Disease Patients
Non-alcoholic fatty liver disease (NAFLD) includes a wide range of disorders that consist of simple fatty infiltration, steatohepatitis (NASH), and end-stage liver disease (cirrhosis).
- Trial name
- NAFLD (NCT04834063)
- Testing
- Serum Zinc a level, serum selenium level, Fibroscan measurement
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver
Feasibility of VIIT in Adults With NASH
The purpose of this study is to determine whether patients with stage 1-3 NASH-related fibrosis are able to complete a single vigorous-intensity interval training (VIIT) session on an indoor rowing machine and provide blood…
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Diseases
- Trial name
- NCT03861819
- Testing
- Vigorous-intensity interval training (VIIT)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Plaque Psoriasis, Non-alcoholic Fatty Liver Disease
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study was to assess the therapeutic efficacy of secukinumab on the psoriatic skin and to explore the anti-inflammatory (reduction of hepatic inflammation and cell damage), anti-steatotic (reduction of hepatic…
- Trial name
- pINPOINt (NCT04237116)
- Testing
- Investigational Arm - secukinumab
- Where
- 8 sites in Germany, Spain
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.